Abstract

BackgroundAn association between rotavirus immunisation and intussusception (IS) has been suggested with present rotavirus vaccines in post-licensure studies. In Finland, rotavirus vaccination programme was implemented in September 2009 using a 2, 3, and 5 months schedule with the pentavalent rotavirus vaccine. By the end of 2013, it is estimated that 719 000 rotavirus vaccine doses have been given in the national programme of which 240 000 were first doses. Nationwide register allows us to evaluate the association between rotavirus vaccination and IS.Methods and MaterialsCases of IS diagnosed during 1999–2013 were identified from National Hospital Discharge Register. All cases under 250 days of age diagnosed during 2009–2013 were confirmed by reviewing medical charts. Self-controlled case-series method was used to assess the risk of IS during 1–21 days compared to 22–42 days post vaccination.FindingsIn register data the relative incidence of IS at 2 months of age between the post and pre vaccination era was 9.1 (95%CI 2.0–84.3). We identified 22 verified cases with date of admission less than 43 days after any of the three rotavirus vaccine doses. The incidence of IS in the risk period after the 1st dose relative to the control period was 2.0 (95% CI 0.5–8.4; p = 0.34.) Number of excess IS cases per 100 000 first vaccine doses was therefore estimated to be 1.04 (95% CI 0.0–2.5), i.e. one additional IS case per 96 000 first doses of rotavirus vaccine (95% CI 54 600 to ∞). There was no risk detected after 2nd and 3rd doses.ConclusionThe finding is in line with the recent published estimates. The benefits of rotavirus immunisation programme outweigh possible small risks of intussusception.

Highlights

  • Already for more than a decade, the link between rotavirus vaccines and intussusception (IS), a bowel syndrome where a segment of the small intestine invaginates within a more distal bowel segment, has been under particular scientific interest

  • After an association was found between the tetravalent rhesus reassortant rotavirus vaccine (RotaShield1) and intussusception in 1999, the manufacturer withdrew the vaccine from the market [1]

  • More than 700 000 doses rotavirus vaccine given as well as national Hospital Discharge Register capturing IS cases, allow us to evaluate the association between rotavirus vaccination and IS in Finnish infants

Read more

Summary

Introduction

Already for more than a decade, the link between rotavirus vaccines and intussusception (IS), a bowel syndrome where a segment of the small intestine invaginates within a more distal bowel segment, has been under particular scientific interest. After an association was found between the tetravalent rhesus reassortant rotavirus vaccine (RotaShield1) and intussusception in 1999, the manufacturer withdrew the vaccine from the market [1]. The two vaccines currently widely used in national programmes underwent extensive safety studies before licensure [2, 3]. Powered to detect significant differences in the rare safety event IS, the pre-licensure clinical trials for both vaccines involved more than 60 000 infants each. In such studies, a risk of the magnitude seen after the first generation rotavirus vaccine 1/4000 to 1/10 000, should have been observed [4].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call